

**ACI Formulations PLC**




**3rd Quarter Ended Report 2024-25  
For the nine months ended on 31 March 2025**

ACI Formulations PLC

Statement of financial position  
Unaudited

Figures in "000"


<i>In Taka</i>	Note	As at 31 March 2025	As at 30 June 2024
<b>Assets</b>			
Property, plant and equipment	5	2,559,361	2,536,705
Right-of-use assets		25,799	31,749
Investments	6	78,828	78,828
<b>Non-current assets</b>		<b>2,663,989</b>	<b>2,647,282</b>
Inventories	8	1,115,006	1,271,844
Trade receivables	9	1,595,877	1,195,760
Other receivables		103,885	48,796
Inter-company receivables	10	2,317,932	1,612,559
Advances, deposits and prepayments	11	140,832	183,819
Current tax assets		413,619	415,209
Cash and cash equivalents		128,076	203,653
<b>Current assets</b>		<b>5,815,228</b>	<b>4,931,638</b>
<b>Total assets</b>		<b>8,479,216</b>	<b>7,578,921</b>
<b>Equity</b>			
Share capital		472,500	472,500
Revaluation reserve		1,442,196	1,442,196
Retained earnings		1,657,623	1,345,681
<b>Total equity</b>		<b>3,572,319</b>	<b>3,260,377</b>
<b>Liabilities</b>			
Employee benefits	12	71,181	63,330
Lease liabilities		22,337	20,782
Deferred tax liabilities		186,303	190,481
<b>Non-current liabilities</b>		<b>279,821</b>	<b>274,593</b>
Bank overdrafts		114,018	204,044
Loans and borrowings		3,740,798	3,031,092
Lease liabilities- current portion		12,169	12,853
Trade payables		64,352	228,638
Other payables	13	673,369	546,343
Unclaimed dividend account	14	1,660	1,350
Inter-company payables	15	20,710	19,630
<b>Current liabilities</b>		<b>4,627,076</b>	<b>4,043,950</b>
<b>Total liabilities</b>		<b>4,906,897</b>	<b>4,318,543</b>
<b>Total equity and liabilities</b>		<b>8,479,216</b>	<b>7,578,921</b>
<b>Net asset value (NAV) per share</b>			
		<b>75.60</b>	<b>69.00</b>

Managing Director

Director

Chief Financial Officer




Company Secretary


ACI Formulations PLC


Statement of profit or loss and other comprehensive income  
Unaudited

<i>In Taka</i>	Note	Figures in "000"			
		For the nine months ended from	For the 3rd quarter ended from		
		July 2024 to March 2025	July 2023 to March 2024	January 2025 to March 2025	January 2024 to March 2024
Revenue	16	4,121,201	4,050,006	1,299,297	1,232,971
Cost of sales	17	(2,737,639)	(2,885,463)	(907,509)	(861,423)
<b>Gross profit</b>		<b>1,383,562</b>	<b>1,164,543</b>	<b>391,788</b>	<b>371,548</b>
Administrative, selling and distribution expenses	18	(648,903)	(638,399)	(226,475)	(212,800)
Other income	19	38,521	53,903	5,329	12,412
<b>Operating profit</b>		<b>773,180</b>	<b>580,047</b>	<b>170,643</b>	<b>171,160</b>
Finance costs, net		(210,543)	(163,871)	(57,705)	(39,058)
<b>Profit before contribution to WPPF</b>		<b>562,637</b>	<b>416,176</b>	<b>112,938</b>	<b>132,102</b>
Contribution to WPPF		(28,132)	(20,808)	(5,647)	(6,604)
<b>Profit before tax</b>		<b>534,505</b>	<b>395,368</b>	<b>107,291</b>	<b>125,498</b>
Tax expenses		(128,063)	(95,050)	(18,433)	(29,662)
<b>Profit after tax</b>		<b>406,442</b>	<b>300,317</b>	<b>88,857</b>	<b>95,836</b>
Other comprehensive income		-	-	-	-
<b>Total comprehensive income</b>		<b>406,442</b>	<b>300,317</b>	<b>88,857</b>	<b>95,836</b>
<b>Earnings per share</b>					
Basic earnings per share (EPS)		8.60	6.36	1.88	2.03

  
Managing Director

  
Director

  
Chief Financial Officer

  
Company Secretary

**ACI Formulations PLC**  
**Statement of changes in equity**  
**Unaudited**

Figures in "000"

For the nine months period ended 31 March 2025				
<i>In Taka</i>	Attributable to owner of the Company			
	Share capital	Revaluation reserve	Retained earnings	Total
<b>Balance at 1 July 2024</b>	472,500	1,442,196	1,345,681	3,260,377
<b>Total comprehensive income</b>				
Profit for the period	-	-	406,442	406,442
<b>Total comprehensive income</b>	-	-	406,442	406,442
<b>Transactions with owners of the company</b>				
Contributions and distributions				
Dividends	-	-	(94,500)	(94,500)
<b>Total transactions with owners of the company</b>	-	-	(94,500)	(94,500)
<b>Balance at 31 March 2025</b>	472,500	1,442,196	1,657,623	3,572,319

For the nine months period ended 31 March 2024				
<i>In Taka</i>	Attributable to owner of the Company			
	Share capital	Revaluation reserve	Retained earnings	Total
<b>Balance at 1 July 2023</b>	472,500	1,442,196	1,140,704	3,055,400
<b>Total comprehensive income</b>				
Profit for the period	-	-	300,317	300,317
<b>Total comprehensive income</b>	-	-	300,317	300,317
<b>Transactions with owners of the company</b>				
Contributions and distributions				
Dividends	-	-	(118,125)	(118,125)
<b>Total transactions with owners of the company</b>	-	-	(118,125)	(118,125)
<b>Balance at 31 March 2024</b>	472,500	1,442,196	1,322,896	3,237,592

ACI Formulations PLC

Statement of cash flows  
Unaudited

Figures in "000"

In Taka	Note	For the nine months ended from	
		July 2024 to March 2025	July 2023 to March 2024
<b>Cash flows from operating activities</b>			
Cash received from customers and others		3,698,275	3,704,460
Cash paid to suppliers and employees		(3,247,571)	(3,043,815)
Cash (used in)/generated from operating activities		<b>450,703</b>	<b>660,645</b>
Paid to WPPF		(22,605)	(16,411)
Interest paid		(132,963)	(143,844)
Income tax paid		(130,653)	(93,057)
		<b>(286,220)</b>	<b>(253,312)</b>
<b>Net cash (used in)/generated from operating activities*</b>	20	<b>164,483</b>	<b>407,333</b>
<b>Cash flows from investing activities</b>			
Acquisition of property, plant and equipment		(58,256)	(113,826)
Sales proceed from disposal		7,339	-
<b>Net cash (used in)/generated from investing activities</b>		<b>(50,917)</b>	<b>(113,826)</b>
<b>Cash flows from financing activities</b>			
Inter-company debts received/(paid)		(704,401)	(622,747)
Proceeds from loans and borrowings		709,706	294,305
Payment for lease liability		(10,232)	(9,267)
Dividends paid		(94,190)	(111,698)
<b>Net cash (used in)/generated from financing activities</b>		<b>(99,118)</b>	<b>(449,407)</b>
Net (decrease)/increase in cash and cash equivalents		<b>14,449</b>	<b>(155,900)</b>
Cash and cash equivalents as at 1 July		(390)	54,895
<b>Cash and cash equivalents as at 31 March</b>		<b>14,058</b>	<b>(101,005)</b>
<b>Closing balance represents</b>			
Cash and cash equivalents		128,076	101,830
Bank overdraft		(114,018)	(202,835)
		<b>14,058</b>	<b>(101,005)</b>
<b>Net operating cash flow per share (NOCFPS)</b>			
		<b>3.48</b>	<b>8.62</b>

\* See Note 20 for reconciliation of net operating cash flow.


**ACI Formulations PLC**  
**Consolidated Statement of Financial Position**  
**Unaudited**

		Figures in "000"	
<i>In Taka</i>	<i>Note</i>	<i>As at 31 March 2025</i>	<i>As at 30 June 2024</i>
<b>Assets</b>			
Property, plant and equipment	5(a)	2,559,370	2,536,751
Right-of-use assets		25,799	31,749
Investments	6(a)	56,880	56,880
Intangible assets	7	5,148	5,148
<b>Non-current assets</b>		<b>2,647,197</b>	<b>2,630,527</b>
Inventories	8(a)	1,115,006	1,271,844
Trade receivables	9(a)	1,596,591	1,196,658
Other receivables		104,642	48,796
Inter-company receivable	10(a)	2,313,257	1,605,921
Advances, deposits and prepayments	11(a)	141,277	184,288
Current tax assets		413,056	414,437
Cash and cash equivalents		129,516	206,682
<b>Current assets</b>		<b>5,813,344</b>	<b>4,928,625</b>
<b>Total assets</b>		<b>8,460,541</b>	<b>7,559,152</b>
<b>Equity</b>			
Share capital		472,500	472,500
Revaluation reserve		1,442,196	1,442,196
Retained earnings		1,656,967	1,342,956
<b>Equity attributable to the owner of the Company</b>		<b>3,571,664</b>	<b>3,257,652</b>
Non controlling interest		2,133	1,985
<b>Total equity</b>		<b>3,573,797</b>	<b>3,259,637</b>
<b>Liabilities</b>			
Employee benefits	12	71,181	63,330
Lease liabilities		22,337	20,782
Deferred tax liabilities		186,303	190,481
<b>Non-current liabilities</b>		<b>279,821</b>	<b>274,593</b>
Bank overdrafts		114,018	204,044
Loans and borrowings		3,740,798	3,031,092
Lease liabilities- current portion		12,169	12,853
Trade payables		64,669	228,955
Other payables	13(a)	673,609	546,628
Unclaimed dividend account	14	1,660	1,350
<b>Current liabilities</b>		<b>4,606,923</b>	<b>4,024,921</b>
<b>Total liabilities</b>		<b>4,886,744</b>	<b>4,299,514</b>
<b>Total equity and liabilities</b>		<b>8,460,541</b>	<b>7,559,152</b>
<b>Net asset value (NAV) per share</b>	21	<b>75.59</b>	<b>68.94</b>





**Managing Director**      **Director**      **Chief Financial Officer**




**Company Secretary**




ACI Formulations PLC


Consolidated statement of profit or loss and other comprehensive income  
Unaudited

In Taka	Note	Figures in "000"			
		For the nine months ended from		For the 3rd quarter ended from	
		July 2024 to March 2025	July 2023 to March 2024	January 2025 to March 2025	January 2024 to March 2024
Revenue	16(a)	4,123,294	4,051,458	1,300,070	1,233,543
Cost of sales	17(a)	(2,737,639)	(2,885,463)	(907,509)	(861,423)
<b>Gross profit</b>		<b>1,385,656</b>	<b>1,165,995</b>	<b>392,561</b>	<b>372,120</b>
Administrative, selling and distribution expenses	18(a)	(649,365)	(638,817)	(226,844)	(212,884)
Other income	19	38,521	53,903	5,329	12,412
<b>Operating profit</b>		<b>774,812</b>	<b>581,081</b>	<b>171,047</b>	<b>171,648</b>
Finance costs, net		(209,088)	(162,954)	(57,234)	(38,718)
<b>Profit before contribution to WPPF</b>		<b>565,724</b>	<b>418,127</b>	<b>113,812</b>	<b>132,930</b>
Contribution to WPPF		(28,132)	(20,809)	(5,647)	(6,605)
<b>Profit before tax</b>		<b>537,592</b>	<b>397,318</b>	<b>108,165</b>	<b>126,325</b>
Income tax expenses		(128,932)	(95,619)	(18,736)	(29,898)
<b>Profit after tax</b>		<b>408,660</b>	<b>301,699</b>	<b>89,429</b>	<b>96,427</b>
<b>Other comprehensive income</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total comprehensive income</b>		<b>408,660</b>	<b>301,699</b>	<b>89,429</b>	<b>96,427</b>
Total comprehensive income attributable to:					
Owners of the Company		408,512	301,600	89,401	96,389
Non controlling interest		148	99	28	38
		408,660	301,699	89,429	96,427
Earnings per share					
Basic earnings per share (EPS)	21	8.65	6.38	1.89	2.04

  
Managing Director

  
Director

  
Chief Financial Officer

  
Company Secretary

ACI Formulations PLC

Consolidated statement of changes in equity  
Unaudited

Figures in "000"

For the nine months period ended 31 March 2025						
<i>In Taka</i>	Attributable to owner of the Company				Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings	Total		
Balance at 1 July 2024	472,500	1,442,196	1,342,956	3,257,652	1,985	3,259,637
Total comprehensive income						
Profit for the period	-	-	408,512	408,512	148	408,660
Total comprehensive income	-	-	408,512	408,512	148	408,660
Transactions with owners of the company						
Contributions and distributions						
Dividends	-	-	(94,500)	(94,500)	-	(94,500)
Total transactions with owners of the company	-	-	(94,500)	(94,500)	-	(94,500)
Balance at 31 March 2025	472,500	1,442,196	1,656,967	3,571,664	2,133	3,573,797
For the nine months period ended 31 March 2024						
<i>In Taka</i>	Attributable to owner of the Company				Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings	Total		
Balance at 1 July 2023	472,500	1,442,196	1,136,137	3,050,833	1,840	3,052,673
Total comprehensive income						
Profit for the period	-	-	301,600	301,600	99	301,699
Total comprehensive income	-	-	301,600	301,600	99	301,699
Transactions with owners of the company						
Contributions and distributions						
Dividends	-	-	(118,125)	(118,125)	-	(118,125)
Total transactions with owners of the company	-	-	(118,125)	(118,125)	-	(118,125)
Balance at 31 March 2024	472,500	1,442,196	1,319,612	3,234,308	1,939	3,236,247



**ACI Formulations PLC**  
**Consolidated statement of cash flows**  
**Unaudited**

<i>In Taka</i>	<i>Note</i>	<b>Figures in "000"</b>	
		<b>For the nine months ended from</b>	
		<b>July 2024 to</b>	<b>July 2023 to</b>
		<b>March 2025</b>	<b>March 2024</b>
<b>Cash flows from operating activities</b>			
Cash received from customers and others		3,700,552	3,705,642
Cash paid to suppliers and employees		(3,248,017)	(3,044,006)
Cash (used in)/generated from operating activities		<b>452,535</b>	<b>661,636</b>
Paid to WPPF		(22,605)	(16,411)
Interest paid		(131,508)	(142,926)
Income tax paid		(131,730)	(93,388)
		<b>(285,842)</b>	<b>(252,725)</b>
<b>Net cash (used in)/generated from operating activities*</b>	<b>20 (a)</b>	<b>166,693</b>	<b>408,911</b>
<b>Cash flows from investing activities</b>			
Acquisition of property, plant and equipment		(58,256)	(113,826)
Sales proceed from disposal		7,339	-
<b>Net cash (used in)/generated from investing activities</b>		<b>(50,917)</b>	<b>(113,826)</b>
<b>Cash flows from financing activities</b>			
Inter-company debts received/(paid)		(708,200)	(624,401)
Proceeds from loans and borrowings		709,706	294,305
Proceeds from share capital		-	-
Payment for lease liability		(10,232)	(9,267)
Dividends paid		(94,190)	(111,698)
<b>Net cash (used in)/generated from financing activities</b>		<b>(102,916)</b>	<b>(451,061)</b>
Net (decrease)/increase in cash and cash equivalents		12,859	(155,976)
Cash and cash equivalents as at 1 July		<b>2,638</b>	<b>57,693</b>
<b>Cash and cash equivalents as at 31 March</b>		<b>15,497</b>	<b>(98,283)</b>
<b>Closing balance represents</b>			
Cash and cash equivalents		129,516	104,552
Bank overdraft		(114,018)	(202,835)
		<b>15,497</b>	<b>(98,283)</b>
<b>Net operating cash flow per share (NOCFPS)</b>	<b>21</b>	<b>3.53</b>	<b>8.65</b>

\* See Note 20(a) for reconciliation of consolidated net operating cash flow.

## ACI Formulations PLC

### Notes to the financial statements as at and for the nine months period ended on 31 March 2025 Unaudited

#### 1 Company profile:

ACI Formulations PLC, a subsidiary of Advanced Chemical Industries PLC, domiciled in Bangladesh. The company's shares are listed with both Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The Principal activities of the company are manufacturing and marketing of a number of agrochemical, consumer brand and paint products.

#### 2 Subsidiaries of ACI Formulations PLC:

##### **Neem Laboratories (Pvt.) Ltd.**

Neem Laboratories (Pvt.) Ltd generate its revenue through royalty fees based on the agreement with ACI PLC effective from 1 July 2019 ; the later currently being engaged in the manufacturing of products under the Neem brand name. Since the Subsidiary showed profitability during the year, its ability to operate as a going concern is not at risk. ACI Formulations PLC through its voting rights controls the operating and financing activities of this entity.

##### **ACI AgroChem (Pvt.) Ltd.**

ACI AgroChem was incorporated on 22nd June 2022 as a limited Company. The principal activities of the Company is to manufacture and marketing of various kinds of agricultural input like chemical including other allied and general chemical. The Company is yet to start its operation. ACI Formulations PLC through its voting rights (90% share holdings of ACI AgroChem Limited) controls the operating and financing activities of this entity.

#### 3 Consolidated Financial statements:

In addition to the separate financial statements, the consolidated financial statements of the company have been prepared and included in this interim financial report as per IFRS 10: Consolidated Financial Statements. In separate Financial Statements, investment in subsidiaries has been carried at cost as per IAS 27: Separate Financial Statements.

#### 4 Selected explanatory notes:

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended 30 June 2024. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

#### 5 Property, plant & equipment

	<u>31-March-25</u>	<u>30-June-24</u>
	<u>Taka</u>	<u>Taka</u>
Opening balance	2,975,340	2,842,467
Addition during the period	58,476	144,098
Adjustment/disposal during the period	(11,306)	(11,225)
	<u>3,022,511</u>	<u>2,975,340</u>
Accumulated depreciation at the end of period	(463,150)	(438,635)
<b>Closing balance</b>	<u><b>2,559,361</b></u>	<u><b>2,536,705</b></u>

**Figures in '000'**

		<u>31-Mar-25</u>	<u>30-Jun-24</u>
		<u>Taka</u>	<u>Taka</u>
<b>5(a)</b>	<b>Consolidated property, plant &amp; equipment</b>		
	Opening balance	2,979,041	2,846,167
	Addition during the period	58,476	144,098
	Adjustment/disposal during the period	(11,306)	(11,225)
		<u>3,026,211</u>	<u>2,979,041</u>
	Accumulated depreciation at the end of period	<u>(466,841)</u>	<u>(442,290)</u>
	<b>Closing balance</b>	<u><b>2,559,370</b></u>	<u><b>2,536,751</b></u>
<b>6</b>	<b>Investments</b>		
	Investment in subsidiaries	21,948	21,948
	Investment in FDR	56,805	56,805
	Investment in shares of ACI Motors Limited	75	75
		<u>78,828</u>	<u>78,828</u>
<b>6(a)</b>	<b>Consolidated investments</b>		
	Investment in FDR	56,805	56,805
	Investment in Shares- ACI Motors Limited	75	75
		<u>56,880</u>	<u>56,880</u>
<b>7</b>	<b>Intangible assets</b>		
	Goodwill on acquisition :		
	Neem Laboratories (Pvt.) Limited	5,148	5,148
		<u>5,148</u>	<u>5,148</u>
<b>8</b>	<b>Inventories</b>		
	Raw and packing materials	526,102	545,673
	Finished goods	565,519	597,674
	Goods in transit	29,223	127,314
	Other inventories	27,354	28,063
	Allowances for slow moving inventory	(33,191)	(26,881)
		<u>1,115,006</u>	<u>1,271,844</u>
<b>8(a)</b>	<b>Consolidated inventories</b>		
	Raw and packing materials	526,102	545,673
	Finished goods	565,795	597,951
	Goods in transit	29,223	127,314
	Other inventories	27,354	28,063
	Allowances for slow moving inventory	(33,468)	(27,158)
		<u>1,115,006</u>	<u>1,271,844</u>
<b>9</b>	<b>Trade receivables</b>		
	Related parties	-	-
	Other than related parties	1,872,465	1,459,581
		<u>1,872,465</u>	<u>1,459,581</u>
	Allowances for doubtful debts	(276,588)	(263,821)
		<u>1,595,877</u>	<u>1,195,760</u>
	Below six months	1,376,223	871,074
	Over six months	496,242	588,507
	Allowances for doubtful debts	(276,588)	(263,821)
		<u>1,595,877</u>	<u>1,195,760</u>
<b>9(a)</b>	<b>Consolidated trade receivables</b>		
	Related parties	-	-
	Other than related parties	1,873,179	1,460,479
		<u>1,873,179</u>	<u>1,460,479</u>
	Allowances for doubtful debts	(276,588)	(263,821)
		<u>1,596,591</u>	<u>1,196,658</u>
	Below six months	1,376,650	871,501
	Over six months	496,530	588,979
	Allowances for doubtful debts	(276,588)	(263,821)
		<u>1,596,591</u>	<u>1,196,658</u>

		<u>31-Mar-25</u> <u>Taka</u>	<u>30-Jun-24</u> <u>Taka</u>
<b>10</b>	<b>Inter-company receivables</b>		
	Advanced Chemical Industries PLC	2,258,433	1,557,718
	ACI HealthCare Bangladesh Ltd.	52,300	48,024
	Neem Laboratories (Pvt.) Ltd.	7,198	6,817
		<u>2,317,932</u>	<u>1,612,559</u>
<b>10(a)</b>	<b>Consolidated inter-company receivables</b>		
	Advanced Chemical Industries PLC	2,260,957	1,557,898
	ACI HealthCare USA Inc.	52,300	48,024
		<u>2,313,257</u>	<u>1,605,921</u>
<b>11</b>	<b>Advances, deposits &amp; prepayments</b>		
	<b>Advances:</b>		
	Staffs	159	259
	Suppliers & others	22,105	24,206
	VAT current account	3,799	22,266
		<u>26,063</u>	<u>46,731</u>
	<b>Deposits:</b>		
	Security deposits	10,146	10,071
	LC Margin	89,640	122,233
	Bank guarantee margin	9,611	4,784
		<u>109,397</u>	<u>137,087</u>
	<b>Prepayments:</b>		
	Prepaid expenses	5,372	-
		<u>5,372</u>	<u>-</u>
		<u>140,832</u>	<u>183,819</u>
<b>11(a)</b>	<b>Consolidated advances, deposits &amp; prepayments</b>		
	<b>Advances:</b>		
	Staff	229	366
	Suppliers & others	22,480	24,568
	VAT current account	3,799	22,266
		<u>26,508</u>	<u>47,200</u>
	<b>Deposits:</b>		
	Security deposits	10,146	10,071
	LC Margin	89,640	122,233
	Bank guarantee margin	9,611	4,784
		<u>109,397</u>	<u>137,087</u>
	<b>Prepayments:</b>		
	Prepaid expenses	5,372	-
		<u>5,372</u>	<u>-</u>
		<u>141,277</u>	<u>184,288</u>
<b>12</b>	<b>Employee benefits</b>		
	Defined benefit obligation	52,258	46,520
	Other employee benefits	18,923	16,810
		<u>71,181</u>	<u>63,330</u>
<b>13</b>	<b>Other payables</b>		
	Creditor for expenses	383,202	359,119
	Advance from customer	925	23,274
	Interest payable	166,421	88,841
	Security money payable	85,449	37,891
	Withholding tax and VAT payable	9,690	15,063
	Workers' profit participation fund	27,682	22,155
		<u>673,369</u>	<u>546,343</u>

		<u>31-Mar-25</u> <u>Taka</u>	<u>30-Jun-24</u> <u>Taka</u>
<b>13(a)</b>	<b>Consolidated other payables</b>		
	Creditor for expenses	383,442	359,404
	Advance from customer	925	23,274
	Interest payable	166,421	88,841
	Security money payable	85,449	37,891
	Withholding tax and VAT payable	9,690	15,063
	Provision for workers' profit participation fund	27,682	22,155
		<u>673,609</u>	<u>546,628</u>
<b>14</b>	<b>Unclaimed dividend account</b>		
	Unclaimed/ unpaid dividend	1,660	1,350
		<u>1,660</u>	<u>1,350</u>
<b>15</b>	<b>Inter-company payables</b>		
	ACI AgroChem Limited	20,710	19,630
		<u>20,710</u>	<u>19,630</u>
		<u>for the period from</u>	<u>for the period from</u>
		<u>July 2024 to</u>	<u>July 2023 to</u>
		<u>March 2025</u>	<u>March 2024</u>
		<u>Taka</u>	<u>Taka</u>
<b>16</b>	<b>Revenue</b>		
	Crop Care & Public Health	3,220,412	3,190,058
	Mosquito Coil	1,231	3,782
	Aerosol	534,900	566,572
	Paint	356,018	277,991
	Others	8,640	11,603
		<u>4,121,201</u>	<u>4,050,006</u>
<b>16(a)</b>	<b>Consolidated revenue</b>		
	Crop Care & Public Health	3,220,412	3,190,058
	Mosquito Coil	1,231	3,782
	Aerosol	534,900	566,572
	Paint	356,018	277,991
	Others	10,733	13,055
		<u>4,123,294</u>	<u>4,051,458</u>

		for the period from	
		July 2024 to March 2025	July 2023 to March 2024
		Taka	Taka
<b>17</b>	<b>Cost of sales</b>		
	Opening stock	1,143,347	1,597,922
	Purchase	2,515,532	2,139,389
	Stock write off	6,548	(1,327)
		<u>3,665,427</u>	<u>3,735,984</u>
	Closing stock	(1,091,621)	(1,016,861)
		<u>2,573,806</u>	<u>2,719,123</u>
	Manufacturing expenses	163,832	166,340
		<u>2,737,639</u>	<u>2,885,463</u>
<b>17(a)</b>	<b>Consolidated cost of sales</b>		
	Opening stock	1,143,347	1,598,198
	Purchase	2,515,532	2,139,389
	Stock write off	6,548	(1,327)
		<u>3,665,427</u>	<u>3,736,260</u>
	Closing stock	(1,091,621)	(1,017,137)
		<u>2,573,806</u>	<u>2,719,123</u>
	Manufacturing expenses	163,832	166,340
		<u>2,737,639</u>	<u>2,885,463</u>
<b>18</b>	<b>Administrative, selling and distribution expenses</b>		
	Administrative expenses	168,103	171,325
	Distribution expenses	96,061	97,017
	Selling expenses	384,739	370,057
		<u>648,903</u>	<u>638,399</u>
<b>18(a)</b>	<b>Consolidated administrative, selling and distribution expenses</b>		
	Administrative expenses	168,565	171,743
	Distribution expenses	96,061	97,017
	Selling expenses	384,739	370,057
		<u>649,365</u>	<u>638,817</u>
<b>19</b>	<b>Other income</b>		
	Sales of Scrap	8,358	7,681
	Dividend Income	20,753	33,205
	Rental Income	1,750	1,343
	Miscellaneous Income	150	252
	Gain/loss on disposal	6,241	10,634
	Unrealized gain/(loss) on translation of foreign currency receivable	1,269	788
		<u>38,521</u>	<u>53,903</u>
<b>20</b>	<b>Reconciliation of net operating cash flow</b>		
		for the period from	
		July 2024 to March 2025	July 2023 to March 2024
<i>In Taka</i>			
	Profit after tax	406,442	300,317
	Adjustment for non cash items and others:		
	- Depreciation and amortization	34,610	34,075
	- Provisions	16,026	25,055
	- Net finance cost	77,580	20,028
	- Unrealized gain/(loss) on translation of foreign currency receivables	(1,269)	(788)
	- Tax expense	(2,589)	1,993
	- Contribution to WPPF	5,527	4,398
	- Gain/ loss on asset disposal	(6,241)	-
	- Dividend income	(20,753)	-
	Changes in:		
	- Inventories	157,076	501,227
	- Trade and other receivables	(471,232)	(424,071)
	- Advances, deposit and prepayments	42,987	(173,530)
	- Trade and other payables, employment benefits' and others	(73,679)	118,629
	Cash generating from operating activities	<u>164,483</u>	<u>407,333</u>

**20 (a) Reconciliation of consolidated net operating cash flow**

<i>In Taka</i>	for the period from	
	July 2024 to March 2025	July 2023 to March 2024
Profit after tax	<b>408,660</b>	301,699
Adjustment for:		
- Depreciation and amortization	<b>34,628</b>	34,445
- Bad debts and inventory loss/(recovery)	<b>16,026</b>	25,055
- Net finance cost	<b>77,580</b>	20,028
- Unrealized gain/(loss) on translation of foreign currency receivables	<b>(1,269)</b>	(788)
- Tax expense	<b>(2,272)</b>	2,231
- Contribution to WPPF	<b>5,527</b>	4,398
- Gain/ loss on asset disposal	<b>(6,241)</b>	-
- Dividend income	<b>(20,753)</b>	-
Changes in:		
- Inventories	<b>157,076</b>	501,227
- Trade and other receivables	<b>(470,950)</b>	(424,341)
- Advances, deposit and prepayments	<b>43,053</b>	(173,269)
- Trade and other payables, employment benefits' and others	<b>(74,371)</b>	118,226
Cash generating from operating activities	<b>166,693</b>	408,911

**21 Consolidated EPS, NAV per Share and NOCFPS:**

	for the period upto	
	July 2024 to March 2025	July 2023 to March 2024
Weighted average number of ordinary shares (in thousand)	<b>47,250</b>	47,250
Consolidated profit attributable to equity holders of the Company (Taka '000)	<b>408,512</b>	301,600
Earnings per share (Taka)	<b>8.65</b>	6.38
Consolidated cash flows from operating activities (Taka '000)	<b>166,693</b>	408,911
Net operating cash flows per share (NOCFPS)	<b>3.53</b>	8.65
	<b>31-Mar-25</b>	<b>30-Jun-24</b>
	<b>Taka</b>	<b>Taka</b>
Consolidated net asset attributable to equity holders of the Company (Taka '000)	<b>3,571,664</b>	3,257,652
Net asset value (NAV) per share	<b>75.59</b>	68.94

Consolidated revenue increased by around 1.77% over Same Period Last Year (SPLY) . Despite that GP increased by around 5% due to decrease of raw material and packing material price in the international market. On other hand, overall operating expenses increased by 1.65 % due to efficient and effective control over operating cost. However, despite having higher financing cost mainly due to higher interest rate and utilization of working capital, higher GP and controlled operating cost led to consolidated profit after tax of Tk. 408.66 Mn against Tk 301.70 Mn of SPLY resulting in higher consolidated EPS and NAV per share. On the other hand, consolidated NOCFPS decreased due to suppliers payment.



## 22 Segment reporting

The Company has four reportable segments, as described below, which are the Company's strategic divisions. The strategic divisions offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic divisions, the Company's CEO reviews internal management reports at least on a quarterly basis. The following summary describes the operations in each of the Company's reportable segments:

**Crop Care and Public Health (CC & PH)** To manufacture and sell crop care and public health products.

**Mosquito Coil (M Coil)** To manufacture and sell mosquito coil products

**Aerosol** To manufacture and sell aerosol and air freshener products.

**Paint** To manufacture and sell of paint products.

Figures in '000'

Particulars	CC & PH		M Coil		Aerosol		Paint		Unallocated		Total	
	For the nine months ended on		For the nine months ended on		For the nine months ended on		For the nine months ended on		For the nine months ended on		For the nine months ended on	
	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24	31-Mar-25	31-Mar-24
	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka
Segment revenue:												
External revenues	3,220,412	3,190,058	1,231	3,782	533,817	566,572	356,018	277,991	8,640	10,406	4,120,117	4,048,809
Inter-segment revenues	-	-	-	-	1,084	-	-	-	2,093	2,649	3,177	2,649
Total revenue	3,220,412	3,190,058	1,231	3,782	534,900	566,572	356,018	277,991	10,733	13,055	4,123,294	4,051,458
Financing costs	(158,221)	(117,016)	(147)	(895)	(25,321)	(19,409)	(23,730)	(23,412)	(1,668)	(2,222)	(209,088)	(162,954)
Depreciation	(18,449)	(16,244)	(8,325)	(10,480)	(4,022)	(3,832)	(3,218)	(3,047)	(595)	(676)	(34,610)	(34,279)
Cost of sales excluding depreciation	(1,901,194)	(2,084,504)	(13,921)	(22,472)	(500,078)	(523,420)	(281,580)	(215,115)	(17,149)	(15,894)	(2,713,921)	(2,861,405)
Operating expenses excluding depreciation	(515,952)	(502,830)	(6,861)	(9,677)	(9,470)	(7,466)	(108,578)	(107,921)	(2,494)	(702)	(643,355)	(628,596)
Other income /(expense)	13,074	10,311	7,287	8,361	803	356	-	383	17,357	34,493	38,521	53,904
<b>Profit before tax</b>	<b>607,686</b>	<b>455,786</b>	<b>(19,700)</b>	<b>(29,812)</b>	<b>(3,028)</b>	<b>12,161</b>	<b>(58,034)</b>	<b>(67,565)</b>	<b>5,875</b>	<b>26,651</b>	<b>537,592</b>	<b>397,318</b>
<b>Reportable segment assets</b>	<b>3,021,681</b>	<b>2,782,410</b>	<b>167,020</b>	<b>178,150</b>	<b>584,468</b>	<b>650,277</b>	<b>626,120</b>	<b>614,987</b>	<b>4,061,252</b>	<b>3,333,328</b>	<b>8,460,541</b>	<b>7,559,152</b>
<b>Reportable segment liabilities</b>	<b>1,395,922</b>	<b>1,116,550</b>	<b>14,576</b>	<b>14,509</b>	<b>150,279</b>	<b>191,911</b>	<b>244,271</b>	<b>208,623</b>	<b>3,081,696</b>	<b>2,767,920</b>	<b>4,886,744</b>	<b>4,299,514</b>

\* Comparative figures of segment assets and segment liabilities are as of 30 June 2024.

23 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.